Trials / Completed
CompletedNCT00151450
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 390 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | |
| DRUG | Venlafaxine XR |
Timeline
- Start date
- 2005-03-01
- Completion
- 2006-11-01
- First posted
- 2005-09-09
- Last updated
- 2021-01-22
Locations
45 sites across 8 countries: Belgium, Canada, France, Ireland, Italy, Netherlands, Spain, Sweden
Source: ClinicalTrials.gov record NCT00151450. Inclusion in this directory is not an endorsement.